The Board of Directors of Pharma Equity Group has approved the issuance of convertible loans totaling up to DKK 10,892,187. The loans can be converted into shares in the company after 23 months, with an interest rate of 10% p.a. The conversion price is set at DKK 0.15 per share. Existing convertible loans of DKK 3,157,895 and DKK 5,842,500, along with a credit facility of DKK 1,502,917, will be repaid. The new shares will be traded on Nasdaq Copenhagen, with a potential increase in share capital of DKK 13,271,072. For more information, contact Christian Tange, CEO, or Christian Vinding Thomsen, Chairman of the Board.

Pharma Equity Group is a listed company on Nasdaq Copenhagen, focusing on promoting drug candidates in its subsidiary, Reponex Pharmaceuticals. The company aims to add value to Reponex Pharmaceuticals’ drug candidates by providing support and expertise for their development. Pharma Equity Group prioritizes innovative medical solutions and treatments, working closely with Reponex Pharmaceuticals. Their long-term strategy includes exploring opportunities for strategic investments in other companies while remaining committed to current projects for growth.

Read more at GlobeNewswire: The Board of Directors’ resolution on the issuance of